Inobrodib exhibits encouraging preclinical and early-phase clinical activity through disrupting the action of p300/CBP at regulatory elements controlling key cancer genes.Inobrodib is the first in a new class of drug with promise in relapsed refractory multiple myeloma and other haematological malignancies.Patients.
CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.